SCHEMBL29782844

SCHEMBL29782844

COc1cccc(S(=O)(=O)N(C)C)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 3/20 0.61
TAS2R14 Q9NYV8 1/20 0.56
ALDH1A1 P00352 2/20 0.56
MAPT P10636 1/20 0.56
TDP1 Q9NUW8 1/20 0.53
CYP11B1 P15538 1/20 0.52
CYP11B2 P19099 1/20 0.52
LMNA P02545 2/20 0.51
NPC1 O15118 1/20 0.51
TNF P01375 1/20 0.51
RAB9A P51151 1/20 0.51
NOD1 Q9Y239 1/20 0.51
KEAP1 Q14145 2/20 0.51
NFE2L2 Q16236 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
FFAR4 Q5NUL3 1/20 0.50
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4952964 1.00 PGR (0.61) PGRTAS2R14ALDH1A1MAPTTDP1
SCHEMBL29931795 0.82 RAB9A (0.49) PGRTAS2R14ALDH1A1MAPTLMNA
SCHEMBL29932025 0.82 RAB9A (0.49) PGRTAS2R14ALDH1A1MAPTLMNA
SCHEMBL7163455 0.82 RAB9A (0.63) ALDH1A1MAPTLMNANPC1TNF
SCHEMBL4616965 0.81 NFE2L2 (0.53) PGRTAS2R14LMNAKEAP1NFE2L2
SCHEMBL23536187 0.81 RAB9A (0.47) PGRTAS2R14ALDH1A1MAPTLMNA
SCHEMBL12896230 0.81 RAB9A (0.47) PGRALDH1A1MAPTLMNANPC1
SCHEMBL3151230 0.80 MTNR1B (0.56) PGRALDH1A1LMNAKEAP1NFE2L2
SCHEMBL31352975 0.80 MTNR1B (0.56) PGRALDH1A1LMNAKEAP1NFE2L2
SCHEMBL29812140 0.79 PGR (0.52) PGRTAS2R14ALDH1A1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12357603-B2 Acyl sulfonamides for treating cancer BAYER AKTIENGESELLSCHAFT (DE) 2025-07-15 US disclosed
US-20220226279-A1 ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. 2022-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220226279-A1 ACYL SULFONAMIDES FOR TREATING CANCER KAT6A, KAT6B, KAT2A PGR 2771/4885TAS2R14 3952/4885ALDH1A1 1645/4885
US-12357603-B2 Acyl sulfonamides for treating cancer KAT6A, KAT6B, KAT2A PGR 2771/4885TAS2R14 3952/4885ALDH1A1 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.